The IPD-pooled analysis results confirm that non-HER2-positive/HER2-negative advanced or metastatic GC or GEJC with a negative PD-L1 expression had no significant PFS benefit from first-line immunotherapy. The gene discussed is CD274; the disease is gastric cancer.